

ATTACHMENT C
Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Original) A method of treating diseased or damaged tissue which comprises administering an agent for mobilizing stem cells.
2. (Original) A method according to claim 1, wherein the diseased or damaged tissue is the liver.
3. (Currently Amended) A method according to claim 1 ~~or~~ 2, wherein the agent comprises at least one regulator of the sympathetic nervous system.
4. (Original) A method according to claim 3, wherein said regulator comprises an adrenoceptor agonist.
5. (Original) A method according to claim 3, wherein said regulator comprises an adrenoceptor antagonist.
6. (Original) A method according to claim 5, wherein said regulator comprises an α -adrenoceptor antagonist or a β -adrenoceptor antagonist.
7. (Original) A method according to claim 6, wherein said regulator comprises an α -1 β -adrenoceptor antagonist for hepatic oval cells.
8. (Original) A method method according to claim 6, wherein said regulator comprises an β 20-adrenoceptor antagonist for hepatic oval cells.
9. (Original) A method according to claim 6, wherein the regulator comprises prazosin.

10. (Original) A method according to claim 6, wherein the regulator comprises propranolol.
11. (Original) Use of an agent for the mobilization of stem cells in the manufacture of a medicament for the treatment of diseased or damaged tissue.
12. (Original) Use according to claim 11, wherein the agent comprises an adrenoceptor agonist.
13. (Original) Use according to claim 11, wherein the agent comprises an adrenoceptor antagonist.
14. (Original) Use according to claim 13, wherein the agent comprises an α -adrenoceptor antagonist or a β -adrenoceptor antagonist
15. (Original) Use according to claim 14, wherein the agent comprises an α -1_B-adrenoceptor antagonist for hepatic oval cells.
16. (Original) Use according to claim 14, wherein the agent comprises an β 2-adrenoceptor antagonist for hepatic oval cells.
17. (Original) Use according to claim 14, wherein the regulator comprises prazosin.
18. (Original) Use according to claim 14, wherein the regulator comprises propranolol.

ATTACHMENT D
Courtesy copy of the Drawings

Attached is a copy of the drawings which should be forwarded to the U.S. Patent Office from WIPO.